Beta Bionics (NASDAQ:BBNX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Beta Bionics (NASDAQ:BBNX) from a hold rating to a sell rating in a research report sent to investors on Sunday morning.

Other equities analysts also recently issued research reports about the stock. Lake Street Capital set a $20.00 target price on shares of Beta Bionics in a research note on Wednesday, February 18th. Bank of America cut shares of Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th. TD Cowen started coverage on shares of Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 price objective for the company. The Goldman Sachs Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Beta Bionics in a research note on Thursday, January 15th. Finally, Robert W. Baird lowered their target price on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.20.

Beta Bionics Price Performance

Shares of NASDAQ BBNX opened at $10.76 on Friday. The stock has a market capitalization of $477.53 million, a PE ratio of -5.52 and a beta of 5.59. Beta Bionics has a one year low of $8.89 and a one year high of $32.71. The business’s fifty day moving average price is $13.06 and its 200-day moving average price is $21.37.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.12. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.The company had revenue of $32.12 million during the quarter.

Insider Buying and Selling at Beta Bionics

In related news, insider Mike Mensinger sold 2,200 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the transaction, the insider directly owned 80,752 shares in the company, valued at approximately $2,430,635.20. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer directly owned 42,614 shares in the company, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 34,705 shares of company stock worth $945,653.

Hedge Funds Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently modified their holdings of the company. GPS Wealth Strategies Group LLC raised its holdings in shares of Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after buying an additional 450 shares in the last quarter. Strs Ohio purchased a new stake in Beta Bionics in the first quarter worth approximately $29,000. EverSource Wealth Advisors LLC boosted its stake in Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after buying an additional 1,594 shares in the last quarter. Summit Securities Group LLC bought a new position in Beta Bionics during the fourth quarter valued at approximately $52,000. Finally, Legal & General Group Plc grew its position in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after acquiring an additional 2,639 shares during the last quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.